Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
about
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injuryIdentification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoformPhosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5.PDE4 as a target for cognition enhancementAssociation with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibitionERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regionsRACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2Temporal and spatial patterns of ovarian gene transcription following an ovulatory dose of gonadotropin in the ratDisease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitorCilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalizationLong PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism.PDE11A associations with asthma: results of a genome-wide association scanAn update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.Micropatterned macrophage analysis reveals global cytoskeleton constraints induced by Bacillus anthracis edema toxin.Predicting the emetic liability of novel chemical entities: a comparative studyPostinjury treatment with rolipram increases hemorrhage after traumatic brain injurySelective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.Modulation of the cAMP signaling pathway after traumatic brain injury.Phosphodiesterase inhibitors.Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.Involvement of type 4 cAMP-phosphodiesterase in the myogenic differentiation of L6 cells.Treating COPD with PDE 4 inhibitors.PDE4 inhibitors: a review of current developments (2005 - 2009).Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model.Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D.Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain.cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases.Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.Novel 5,6-dihydropyrazolo[3,4-E][1,4]diazepin-4 (1H)-one derivatives for the treatment of asthma and chronic obstructive pulmonary disease.Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.Identification of inhibitor specificity determinants in a mammalian phosphodiesterase.
P2860
Q21089854-3A9C4830-32A0-486C-ADBA-4ACDE150BB06Q24317630-EC56FC43-8340-4094-B025-D0E3D997C4B3Q24533566-35B34422-8965-4733-BE5E-CDAD75E837C3Q24535564-C64B3733-E576-4C6B-A2F5-1E20D375765BQ24633622-6A969E97-6F82-47AC-8823-93501ABA0A21Q24801846-F768FD47-4F2A-4FE1-8B82-2FC196BACF4CQ27008296-72BB06EE-8D8E-44E0-8EC7-70D3BDF3FE1FQ28141780-EEF3E1CD-E38A-4A07-B9EC-08D0FDABD2D6Q28145238-757DF484-88BD-4D9A-BC6D-7C73743FEFFAQ28386161-497BA194-0130-41EE-809B-07D98313CB1DQ28573529-C8FDFCDF-ED9D-43DE-8414-358C899765F6Q28582867-01892F08-3610-46CD-9AA3-41FF4F148F94Q34128422-37C9339C-56A0-4F09-AF96-510E853F91C8Q34481601-A0A52B07-F47A-47AC-A3E1-29B4619D71ECQ35005680-A34967B3-E292-4A81-A0B0-27FF8DFD1E34Q35044409-4B847BD4-5A98-4498-83A9-FE52D5280E73Q35047671-2DE88DBA-8516-4BF4-8405-25A532A87D24Q35096782-2F760DD3-1855-4928-B60D-4D84D41E9F74Q35827644-DAAA6E7D-E8E7-4C15-A5F0-006C2D9CF6BDQ35833792-4EF77980-F785-424C-9AEF-B2A2BABF3793Q36025372-39CEC705-92A1-4610-A2D5-EAC034AEA2C0Q36162694-FE6BB64E-836D-4117-9F13-BA3F269E423BQ36165890-0A0618E5-D548-42A5-89DE-8261035490A0Q36276090-24C1BFA5-BE60-48A8-AA94-20421DE6B23CQ36364429-E3A68235-7F1C-4182-A06D-D37DD71E902CQ36677411-2EA26C2D-D602-4F64-8AC1-CF3824622D94Q36792648-3C1CFE77-CF54-4D90-86B2-1E51CCB0B15DQ36957171-56FBF92E-8C37-4E56-8596-E159593BF724Q37082594-A229144B-870D-49C0-A27D-2277A6B3F3BEQ37615398-2443779D-6DEF-43B5-A214-60D3E74EBFD2Q37719421-1E1296F9-718D-446E-938D-A4C39BF36B31Q39656356-A8299F1A-9209-4A00-A855-79E989D70518Q40944581-A28AD3BB-FB15-4AFE-8220-A765B8A45CE7Q41030925-0230B19D-4C32-40D0-A70D-046C4F48ABABQ41708863-A9EE81A4-8DA7-40B7-9B15-9B481D367EB8Q41771251-CD45B715-2D52-493A-9EA8-671618B3868DQ42025731-022887D4-BCB3-438A-BBEC-BEACEFC851A2Q42975073-0A6FE208-B7AB-4077-862C-A767259A79C9Q43061572-CE9C4B12-014E-44F2-83DB-95EEE6C7CF76Q43744925-B1DC7E07-E9D7-4289-8712-146620384D10
P2860
Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
@en
type
label
Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
@en
prefLabel
Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
@en
P1433
P1476
Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
@en
P2093
P304
P356
10.1016/S0898-6568(96)00173-8
P577
1997-05-01T00:00:00Z